Meta AnalysisID 7138
三氧化二砷治疗原发性肝细胞癌：一项系统评价与Meta分析
CRD42023457874
Research focused on therapeutic effects of As2O3 used on participants diagnosed with primary hepatocellular carcinoma
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Herb: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7138
- Evidence Id
- 15696
- Core Evidence Id
- 15696
- Source Meta Analysis Id
- 7125
- Herb2 Meta Analysis Id
- HBMA007125
- Crd Id
- CRD42023457874
- Title
- Arsenic trioxide treated for primary hepatocellular carcinoma: A systematic review and meta-analysis
- Review Question
- Research focused on therapeutic effects of As2O3 used on participants diagnosed with primary hepatocellular carcinoma
- Study Type Included
- RCT
- Condition Being Studied
- primary hepatocellular carcinoma
- Participant
- participants diagnosed with primary hepatocellular carcinoma
- Animal
- Human Disease Modelled
- Intervention
- Arsenic Trioxide
- Comparator Control
- placebo
- Main Outcome
- complete response (CR), partial response (PR), stable disease(SD), and progressive disease (PD), half year survival rate, 1-year survival rate, 2-year survival rate, 3-year survival rate, improvement rate of karnofsky performance scale (KPS) scores, maintaining rate of KPS scores, and various adverse events Measures of effect The clinical benefit rate (CBR) was defined as the percentage of CR, PR, and SD patients, and the clinical effective rate (CER) was defined as the percentage of CR and PR patients. Data of risk ratios (RR) were pooled using a random effects model to give a more conservative estimate of the effect of As2O3 therapy on the subsequent occurrence of CER and CBR, allowing for any heterogeneity. Heterogeneity between studies was assessed using both the I² statistic with a cut off of ≥50% and the χ² test with a p value <.10 used to define a significant degree of heterogeneity.
- Outcome Measure
- Additional Outcome
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Humans; Liver Neoplasms
- Contact
- Yan Cai [email protected]
- Organisational Affiliation
- Zhejiang Chinese Medical University
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-08-26
- Registration Date
- 2023-09-06
- Anticipated Start Date
- 2023-09-01
- Anticipated Completion Date
- 2023-10-31
- Title Cn
- 三氧化二砷治疗原发性肝细胞癌：一项系统评价与Meta分析
- Title En
- Arsenic trioxide treated for primary hepatocellular carcinoma: A systematic review and meta-analysis
- Bilingual Status
- complete